Keyword: SV Health Investors
Martin Williams is now CEO of Caraway Therapeutics, a biotech aiming at the cell’s garbage disposal to treat neurodegenerative diseases.
CRUK is set to invest $25 million in SV’s new biotech fund and work with its new partner to pick out research to develop externally.
Rheostat Therapeutics raised $23 million to develop treatments for neurodegenerative and rare diseases by targeting the cell’s garbage disposal.
The Dementia Discovery Fund capped its fundraising at $350 million; it was nudged across the line by a $60 million investment from AARP.
PanOptica plans to start trialling the small molecule anti-vascular endothelial growth factor eye drop early next year.
SV Health Investors (formerly SV Life Sciences) has closed its sixth fund, hitting its target of $400 million, as the firm itself also registers a numbers growth.
SV Life Sciences has joined with the VC wings of AbbVie and Merck KGaA to funnel $33.2 million into a DNA damage repair startup.
SV Life Sciences has raised well over half of the $400 million it announced it was seeking last year for its sixth life science upstart fund--but this falls below previous targets that have been around the $500 million mark.